anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
NEW MATERIAL:A 5,6-dihydro-4-pyrimidone derivative shown by the formula  I (R&lt;1&gt; is lower alkyl; R&lt;2&gt; is phenyl, substituted phenyl, furyl, thienyl, or pyridyl). EXAMPLE:5-Ethoxycarbonyl-2-methyl-6-phenyl-5,6-dihydropyrimidin-4-one. USE:Having a vasodilating action on coronary blood vessels, useful as a remedy for various kinds of diseases of circulatory organs. Useful for remedying a wide range of diseases such as angina pectoris, hypertension, arrhythmia, disorders of cerebral circulation, etc. PREPARATION:A propenoic ester shown by the formula II is heat-treated with acetamidine and its salt in the presence of an alcolate of an alkali metal such as lithium ethoxide, etc. in an alcoholic solvent, to give a compound shown by the formula I . The compound shown by the formula II is synthesized by condensing a dialkyl malonate with an aldehyde through dehydration in the presence of a base in a solvent under reflux by heating.
PURPOSE:To obtain a crystallized calcium phosphate glass for dental material having transparent and beautiful appearance, by melting a calcium phosphate mixture having specific atomic ratio of Ca/P under normal pressure, cooling the molten mixture, and again melting under reduced pressure. CONSTITUTION:A Calcium phosphate mixture having an atomic ratio (Ca/P) of 0.35-1.7 is melted under atmospheric pressure, and cooled to obtain glass. The glass is melted again under reduced pressure of about &lt;=100Torr, returned to the atmospheric pressure, and cast by a lost-wax process. The cast glass is crystallized by beat-treatment. The water, air, carbon dioxide gas, etc. existing in the glass can be removed, and transparent feeling can be attained by the crystallization of the glass. The damage of the crucible and the furnace can be decreased compared with the case of direct melting.
Indazole-derivatives as factor Xa inhibitors. The present invention relates to compounds of the formula (I), wherein R&lt;0&gt;, R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, Q, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gel-like composition from which high strength and highly transparent gel is obtained.  &lt;P&gt;SOLUTION: The gel-like composition contains following components (A) to (C), and is characterized in that the content of cellulose fibers of the component (A) is 0.3 to 3.0 wt.% based on the total amount of the gel-like composition. The component (A) is cellulose fibers having the maximum fiber diameter of ≤1,000 nm and a number-average fiber diameter of 2 to 100 nm, wherein the cellulose has I-type crystal structure, and the hydroxy group at the C6-position of each glucose unit in the cellulose molecule is selectively oxidized into aldehyde group or carboxy group, and the amount of the carboxy groups is within the range of 0.6 to 2.2 mmol/g. The component (B) is polyvinylpyrrolidone. The component (C) is water.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A system for monitoring the reaction of a user and for adjusting output content based on the user&#39;s reaction includes an output unit, a monitoring unit, a synchronization unit, an analysis unit and a control unit. The output unit presents content to the user. The monitoring unit monitors a user parameter during a period during which a first content is presented to the user in order to obtain monitoring data from the user. The monitoring data is synchronized during the period with the first content so as to link in time the monitoring data and the first content. The analysis unit analyzes the monitoring data and links it to the first content in order to determine the user&#39;s reaction to the first content. The control unit controls the output unit to present a second content to the user that is selected based on the user&#39;s reaction to the first content.
The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF). The methods provide for efficiently removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents. The invention finds use as a diagnostic, therapeutic and drug delivery platform for a variety of diseases affecting the CNS by accessing the CSF space. Exemplified disease conditions treatable by the present CSF processing systems and methods include, but are not limited to: Cerebral Vasospasm, Guillain Barre Syndrome, Alzheimer&#39;s, Parkinson&#39;s, Huntington&#39;s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Stroke, Cancer affecting the brain or spinal cord, Prion disease, Encephalitis from various causes, Meningitis from various causes, diseases secondary to enzymatic or metabolic imbalances, Biological Warfare, etc. For the first time, the present invention offers patients a disease-modifying, disruptive technology treatment platform that addresses the known disease pathogenesis of a number of neurologic conditions to which there are presently limited and ineffective treatment options.
Systems and methods for tracking samples via sample tracking chains are presented. Sample tracking chains represent digital data structures instantiated according to intrinsic properties of a sample. Each link in the chain is a block of data representing an observed intrinsic state of the sample and is linked at least to a previous block representing a previous state. The sample tracking chain and blocks can be indexed for later retrieval by the intrinsic properties of the corresponding sample&#39;s state. The sample tracking chain can take the form of a blockchain possibly stored as part of a private or public distributed ledger. Disclosed sample tracking chains provide a full life cycle audit trail for sample processing.
A solution for the preservation, transport and application of stem cells for medical utilisation, that consists ofa buffer water solution of trehalose. The solution contains cations K+ in a quantity of 20 to 50 mmol/1, cations Na+ in a quantity of 20 to 80 mmol/1; anions CI&#34; in a quantity of 0.5 to 40 mmol/1, anions PO43&#34; and/or HPO42&#34; and/or H2PO4&#34; in a total quantity of 20 to 65 mmol/1, and trehalose in a quantity of 60 to 300 mmol/1 as necessary components. The concentration of the components has been selected in such a way that the pH of the solution is 7.1 to 7.6. The solution is intended for storing the cells at a temperature of - 4 °C to 25 °C, advantageously 0 °C to 8 °C, and most frequently 4 °C to 6 °C. Adequate viability of the cells is kept for a period of at least 72 hours.. The solution consists of pharmaceutically acceptable compounds, and it can be used for application of the stem cells that are kept directly within. The solution containing the stem cells is intended for the treatment of inflammatory diseases including post-traumatic inflammatory reactions after damage or injury, as well as for treatment of degenerative and neurodegenerative diseases. The solution containing the stem cells can also be used for the treatment of trauma, of developmental defects, for healing of wounds and skin burns, for tissue replacement, for treatment of locomotion system diseases (tendons, joints, inflammatory diseases, arthritis, and osteoarthritis), bone defects, diabetes, attacks, and cardiological and oncological diseases.
Physiologically active amino compounds related to pyridoxine are manufactured by heating pyridoxine or an ester thereof with ammonia or ammonium carbonate, preferably to at least 100 DEG  C. and advantageously in the presence of a solvent for the reactants, e.g. methanol or ethanol (with or without up to about 50 per cent of water), water alone (less satisfactorily), or dioxane.  The reaction mixture may be worked up by neutralization or evaporation to dryness, or by treatment with picric acid to precipitate the picrate and decomposing this with hydrochloric acid to form the dihydrochloride, from which the free amine may be obtained by the action of caustic soda.  An example describes the treatment of pyridoxine triacetate, and other starting materials specified are the triesters of pyridoxine with azobenzene-4-carboxylic acid and 4 : 5-diesters of pyridoxine such as the 4 : 5-diacetate.  The Specification as open to inspection under Sect. 91 comprises also the use, as starting materials, of other compounds of the general formula &lt;FORM:0603289/IV(b)/1&gt; wherein R represents methyl, hydroxymethyl or etherified hydroxymethyl and R1 hydroxymethyl or etherified hydroxymethyl, and their esters, e.g. 2 : 4-dimethyl-3-acyloxy-5-acyloxymethylpyridines, 2-methyl-3-acyloxy-4-methoxymethyl - 5 - acyloxymethylpyridines and 2 - methyl-3-acyloxy-4 : 5-epoxydimethylpyridines.  This subject-matter does not appear in the Specification as accepted.
Preparation of an extract from Petasites hybridus (I), which is practically free of pyrrolizidine alkaloid compounds and their N-oxide derivatives, by continuous extraction.  Also claimed is the use of (I).  Preferably extract is practically free of pyrrolizidine alkaloids and/or their N-oxide. Additional plant extracts may include valerian, passion flower, or balm extract. Extraction is continuous (see Figure 1). Pyrrolizidine alkaloids are removed using an ion-exchange material (preferably a cationic exchange medium based on an acidic polystyrene resin in the H&lt;+&gt; form). An alcoholic solvent is used for extraction.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical management system allowing usage of a particular type of a medical apparatus even to a medical institution incapable of installing the medical apparatus.  &lt;P&gt;SOLUTION: A medical apparatus management computer 11 is attached to the medical apparatus 10. A host computer 20 is connected to the medical apparatus management computer 11 and a reception computer 30 is connected to the host computer 20 through a communication network respectively. The reception computer 30 sends a usage application for the medical apparatus 10 along with data regarding a usage applicant to the host computer 20. The host computer 20 prepares operation data of the medical apparatus 10 on the basis of the received data, and it sends the operation data to the medical apparatus management computer 11. The medical apparatus management computer 11 displays the received operation data and/or it transmits a control command based upon the operation data to the medical apparatus 10, and it acquires physical/physiological data of a user during medical apparatus usage.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PURPOSE: To provide a method for producing a solid enteric pharmaceutical preparation excellent in acid resistance by which a medicine is coated with a coating liquid containing a dispersed polymer having &lt;=1μm average particle diameter. CONSTITUTION: A cellulosic polymer is dissolved in an organic solvent mixable with water in an optional proportion or a mixed solvent thereof with water to prepare a polymer solution. which is subsequently mixed with water. The organic solvent is then removed to provide a concentrate. An anionic surfactant is subsequently added to the resultant concentrate and the prepared mixture is dried to afford a polymer powder. which is then charged into water to thereby afford an emulsion containing the polymer dispersed into &lt;=1μm average particle diameter. The resultant emulsion is subsequently dispersed in water containing a plasticizer to provide a coating liquid. A medicine is coated with the coating liquid to complete the production of a solid enteric pharmaceutical preparation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic topical composition, having safe, effective and versatile action mechanism and achieving medication compliance of a patient.  &lt;P&gt;SOLUTION: A therapeutic composition for treating skin conditions and dermatoses is provided. The treatable skin conditions and dermatoses include acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, optical aging and actinic keratosis, and eczema; but are not limited thereto. The therapeutic compositions indicated herein are sponge species, more specifically, a freshwater sponge. One of the embodiment originates in Spongilla species, and is prescribed together with a pharmaceutically acceptable vehicle.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Amino acid-based poly(ester urea)s (PEU) are emerging as a class of polymers that have shown promise in regenerative medicine applications. Embodiments of the invention relate to the synthesis of PEUs carrying pendent “clickable” groups on modified tyrosine amino acids. The pendent species include alkyne, azide, alkene, tyrosine-phenol, and ketone groups. PEUs with M w  exceeding 100k Da were obtained via interfacial polycondensation methods and the concentration of pendent groups was varied by copolymerization. The incorporation of derivatizable functionalities is demonstrated using  1 H NMR and UV-Vis spectroscopy methods. Electrospinning was used to fabricate PEU nanofibers with a diameters ranging from 350 nm to 500 nm. The nanofiber matricies possess mechanical strengths suitable for tissue engineering (Young&#39;s modulus: 300±45 MPa; tensile stress: 8.5±1.2 MPa). A series of bioactive peptides and fluorescent molecules were conjugated to the surface of the nanofibers following electrospinning using bio-orthogonal reactions in aqueous media.
The novel positively charged pro-drugs of oxicams and related compounds of the general formula (1) &#39;Structure 1&#39; were designed and synthesized. The positively charged amino groups of these pro-drugs not only greatly increase the solubility of the drugs, but also bond to the negative charge on the phosphate head group of membranes and push the pro-drug into the cytosol. The results indicate that the pro-drugs permeate human skin approximately 100 times faster than oxicams and related compounds. Plasma drug concentrations peak 1-2 hours after oral administration of oxicams and related compounds, whereas these pro-drugs require only about 50 minutes to reach peak plasma drug concentrations upon transdermal administration. In plasma, more than 90% of the pro-drugs can return to the parent drug structure within a few minutes. These prodrugs can be used to treat any oxicams-treatable conditions in humans or animals. Second, the prodrug can be administered not only orally but also transdermally for any kind of medical treatments and avoids most of the side effects of oxicams. Controlled transdermal administration systems of these pro-drugs can stabilize the concentration of oxicams and related compounds in the blood at optimal therapeutic blood levels, enhance therapeutic efficacy and reduce the side effects of oxicams and related compounds. Another great benefit of transdermal administration of these prodrugs is that administration is more convenient, particularly to children.
A composition for controlling or preventing progression of glaucoma comprises a material that reduces or inhibits production of a TGF-.beta. isoform or a chemokine or cytokine that stimulates expression of a TGF-.beta. isoform. The material can comprise a dissociated glucocorticoid receptor agonist (&#34;DIGRA&#34;), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can further comprise an antagonist to TGF-.beta.. It is administered to a patient who has undergone glaucoma filtration surgery to ensure a functioning filtering bleb following such surgery.
Methods of imaging a portion of a body of a patient are provided. In the methods, a contrast agent including an iso-osmotic contrast agent is administered to the patient. In a preferred embodiment, the iso-osmotic contrast agent comprises polyethylene glycol (PEG) and electrolytes, which make the PEG iso-osmotic. In a preferred embodiment, a positive contrast agent, such as an iodine-based contrast agent, is added to the PEG. The iso-osmotic contrast agent can be administered in volumes that are lower than previous contrast agents. The iso-osmotic contrast agent can be administered in combination with a positive intravenous contrast agent. At least one image of the portion of the patient&#39;s body is obtained, such as by computed tomography, after the contrast agent is administered. The methods can be used to image a pelvis, GI tract, and/or appendix of the patient. Iso-osmotic contrast agents are also provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for synthesizing cytoxazone having immunosuppressive effects from a readily available raw material in an extremely simple and safe process.  &lt;P&gt;SOLUTION: The method for synthesis is carried out as follows. Inexpensive p-methoxycinnamic alcohol is used as the starting raw material and epoxidation and azidation are achieved in the same vessel by an aqueous reaction. Reduction with triphenylphosphine and a reaction with potassium cyanate are then conducted. A treatment with nitrous acid or a nitrite is finally carried out to synthesize the racemic cytoxazone represented by formula 1 in high yield in the inexpensive, safe and efficient process.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a manufacturing method of a cosmetic which is capable of producing with good productivity a cosmetic which can obtain whitening action and skin rejuvenating action, excellent in moistening property and excellent in amenity, that is, hardly generating harm, irritation, etc., when applied to the skin, nor generating nasty smell by fermentation of bran.  &lt;P&gt;SOLUTION: This manufacturing method comprises: a fermentation process in which a new fermented bran is obtained by fermenting a bran comprising a mixture of at least one selected from the group consisting of rice bran, wheat bran and bran, using as seed a microorganism which is adsorbed on the fermented bran which is obtained by fermenting a bran comprising a mixture of at least one selected from the group consisting of rice bran, wheat bran and bran using a microorganism at least one selected from genus Bacillus; and a kneading process in which 180-700 pts.wt. of honey and 0.5-40 pts.wt. of mealy royal jelly whose water is eliminated are kneaded to 100 pts.wt. of the fermented bran having a water activity of 0.5-0.8.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention provides a mecobalamin tablet and a preparation method thereof. The mecobalamin tablet is composed of a tablet core and a film coating layer. The weight of the film coating layer is 3-5% that of the tablet core. The tablet core comprises, by weight percentage, 0.5-1% of mecobalamin, 87-93.5% of filler, 5-10% of adhesive and 1-2% of lubricant. Raw materials and auxiliary materials of the prescription amount are sieved, premixed and pelletized and undergo dry method tabletting, coating solution preparation, coating and packaging to obtain the mecobalamin tablet. The mecobalamin tablet and the preparation method thereof have the advantages that the mecobalamin tablet is high in active ingredient content, inter-assay reproducibility and good in stability, the bioavailability of the mecobalamin tablet is improved remarkably, a patient&#39;s compliance is improved, the medicine stability is improved, the production cost is reduced, and the production efficiency is improved.
The invention relates to medicine. Purpose - increase of human&#39;s efficiency under extreme conditions and subsequent restoration of professional efficiency and functional rehabilitation. The method is carried out in the following way. A human administers pharmacological preparations specially selected in optimum composition and, increasing organism stability and its efficiency. The selected pharmacological preparations are administered in steps - before the work under extreme condition is initialized, during and after its completion. At the last step after completion of the work preparation are administered having a wide range of psychotropic properties.
PURPOSE:To obtain a proliferation-promoting agent for Bifidobacterium, having higher selective and excellent proliferation promoting action than conventional bifidus factor, by using a bottle gourd food as an active component. CONSTITUTION:Fruit of bottle gourd is formed in desired form such as ribbon, powder, granule, tablet, etc., to obtain a bottle gourd food. The food may be an unsterilized one or sterilized with steam under a steam pressure of 0.2-0.4kg/cm&lt;2&gt; for 5-20min or alcoholic sterilization for 1-30 days in the presence of 15-150g/kg of an alcohol or may be fumed with sulfuric acid. The sterilized bottle gourd food contains &lt;=5X10&lt;3&gt;/g of general living bacterial cells, in negative to E.coli and Salmonella, contains &lt;=8% of water and is extremely safe in view of food sanitarity. The bottle gourd food may be added with a fiber component, an excipient, a sweetener component, etc., and used as a proliferation-promoting agent. The bottle gourd food used as an active component can be eaten as it is in the form of ribbon or plate after cooking or by forming to powdery form or tablet, etc.
Differenciated neuronal cells suitable for transplantation in individuals with a dopamine deficiency are derived from progenitor cells. The progenitor cells are treated with at least one inducing agent such as retinoic acid for a time period sufficient to optimize expression of tyrosine hydroxylase. The cells intented for transplantation are optionally treated with a lithium salt to enhance bcl-2 production and survival. Optionally, the progenitor cells are co-cultured with Sertoli cells, bone marrow stem cells, or a combination thereof. The transplantation-ready cells are isolated and harvested. The resulting neuronal cells are purified and have a phenotype optimized to treat a dopaminergic deficiency, such as Parkinson&#39;s Disease. Optionally the neuronal cells can be implanted with Sertoli cells, bone marrow stem cells or a combination thereof. A purified human dopaminergic cell type is obtained by culturing NT2 cells and treated for about three weeks with an inducing agent, culturing for about two weeks with growth media without an inducing agent or mitotic inhibitor, culturing for about one week with at least one mitotic inhibitor, harvesting and placing in a diluent.